Introduction Anti-Xa serves as a clinical surrogate for assessing the efficacy and bleeding
risk in patients treated with enoxaparin for thromboembolic events. Evidence from the …

Introduction Given the rising incidence of venous thromboembolism (VTE) and insufficient
thromboprophylaxis dosing evidence in certain patients, the precise monitoring of anti‐Xa …

Abstract Study Objective The objective of the study was to assess clinical outcomes
(composite of any venous thromboembolism [VTE], any bleeding, and mortality) associated …

The reported incidence of venous thromboembolic events (VTE) in neurosurgery is widely
variable, due to the high heterogeneity of study designs, 1, 2 and a wide range of surgical …

Background Enoxaparin is an anticoagulant used for pharmacologic thromboprophylaxis in
pediatrics. Enoxaparin pharmacokinetics can be altered in the setting of obesity. Optimal …

En raison de l'augmentation de l'utilisation des anticoagulants dans la population ces
dernières années, la prise en charge de ces patients est devenue une pratique quotidienne …

Texte validé par la Commission des référentiels de la Société française de médecine
d'urgence (SFMU) le 10 novembre 2023 et par le Comité des référentiels cliniques de la …

Methods: The addressed questions were defined by 40 experts (GIHP, SFAR, SFTH and
SFMV) and formulated in a PICO format. They performed the literature review and …